To begin, complete the form below.
Spravato® treatment is an FDA-approved intranasal esketamine treatment used for treatment-resistant depression.
It is administered in a monitored clinical setting and used alongside an oral antidepressant as part of a broader treatment plan.
This is an advanced intervention reserved for specific clinical situations. It is introduced thoughtfully and only after careful evaluation.
Eligibility is determined through structured evaluation.
Spravato is not appropriate for:
Careful screening is required before treatment is recommended.
Each treatment visit includes:
Medication administration in clinic
Post-administration monitoring
Safety assessment before discharge
Treatment follows a structured schedule during the initial and maintenance phases.
Some patients may experience:
Dissociation
Sedation
Temporary increases in blood pressure
Nausea
Because of these effects, monitoring is required after each treatment session.
Response varies between individuals. Some patients experience meaningful improvement, while others may require additional strategies or maintenance planning.
Careful screening helps ensure the treatment is used appropriately and increases the likelihood of benefit.
Degree of sustained improvement
Ongoing medication needs
Maintenance or relapse-prevention strategies
Advanced treatments are integrated carefully and intentionally, not used reactively.
Spravato is an FDA-approved intranasal form of esketamine used for treatment-resistant depression. Unlike traditional antidepressants, which primarily affect serotonin or related neurotransmitters, Spravato works through a different brain pathway involved in glutamate signaling. Because of this different mechanism, it may help some patients who have not responded to standard medications.
Spravato is administered in the clinic under medical supervision. After the medication is given, patients remain in the clinic for a monitoring period so that clinicians can observe for side effects and ensure safety before discharge.
Response times vary between individuals. Some patients begin to notice improvement within the first few weeks of treatment, while others require a longer course. Because depression is complex, Spravato is typically integrated with other treatments such as medication management and psychotherapy.
Spravato has been studied extensively and is FDA-approved for specific forms of depression. However, it can cause temporary side effects such as dissociation, sedation, or increases in blood pressure. For this reason, treatment must be administered in a monitored clinical setting with appropriate medical oversight.
Visit our Resources page for additional patient education documents and Spravato specific resources.
If depression remains severe despite appropriate treatment, we can evaluate whether Spravato may be a reasonable next step.
Advanced treatments should be introduced with a clear understanding of potential benefits, risks, and expectations.
